Brought to you by 
ImmunoGen, CytomX swap licenses to develop anti-cancer Probody-drug conjugates
03 Feb 2023
Executive Summary
In a multi-year deal, next-generation antibody developer CytomX Therapeutics Inc. and ImmunoGen Inc. (antibody-drug conjugates; ADCs) agreed to develop anti-cancer Probody-drug conjugates (PDCs) against a certain number of targets. (NOTE: the lab code of one candidate is CD166, and another is CX2009).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Technologies
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ImmunoGen, CytomX swap licenses to develop anti-cancer Probody-drug conjugates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice